ProMIS Neurosciences (PMN) announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310, the Company’s lead therapeutic antibody candidate for the treatment of AD. The Company remains on track to conduct a blinded 6-month interim analysis in Q2 2026, including an evaluation of key plasma and cerebrospinal fluid biomarkers, followed by final unblinded 12-month top-line analysis expected in Q4 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences Regains Nasdaq Compliance
- ProMIS Neurosciences announces publication highlighting PMN310
- ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate
- ProMIS Neurosciences: Buy Rating Affirmed Amid Promising PMN310 Progress and Favorable Valuation
- ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright